Drugs interactions for

  • 68 Major drug interactions (including ingredients like Abametapir, Abemaciclib, Abemaciclib)
  • 710 Moderate drug interactions (including ingredients like Abrocitinib, Acarbose, Acebutolol)
  • 914 Minor drug interactions (including ingredients like Abacavir, Abacavir, Abaloparatide)
1692 interactions for
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and .
Abametapir
The serum concentration of Canagliflozin can be increased when it is combined with Abametapir.
Abemaciclib
The excretion of Abemaciclib can be decreased when combined with Metformin.
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Canagliflozin.
Amiodarone
The metabolism of Canagliflozin can be decreased when combined with Amiodarone.
Atazanavir
The metabolism of Canagliflozin can be decreased when combined with Atazanavir.
Axitinib
The serum concentration of Axitinib can be increased when it is combined with Canagliflozin.
Bendamustine
The serum concentration of Bendamustine can be increased when it is combined with Canagliflozin.
Binimetinib
The serum concentration of Binimetinib can be increased when it is combined with Canagliflozin.
Bortezomib
The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin.
Cabergoline
The serum concentration of Cabergoline can be increased when it is combined with Canagliflozin.
Carfilzomib
The serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.
Ceritinib
The serum concentration of Ceritinib can be increased when it is combined with Canagliflozin.
Clarithromycin
The metabolism of Canagliflozin can be decreased when combined with Clarithromycin.
Cobimetinib
The serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.
Conivaptan
The metabolism of Canagliflozin can be decreased when combined with Conivaptan.
Crizotinib
The serum concentration of Crizotinib can be increased when it is combined with Canagliflozin.
Curcumin
The metabolism of Canagliflozin can be decreased when combined with Curcumin.
Cyclosporine
The serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.
Dacomitinib
The serum concentration of Dacomitinib can be increased when it is combined with Canagliflozin.
Dactinomycin
The serum concentration of Dactinomycin can be increased when it is combined with Canagliflozin.
Danazol
The metabolism of Canagliflozin can be decreased when combined with Danazol.
Darunavir
The metabolism of Canagliflozin can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.
Elvitegravir
The metabolism of Canagliflozin can be decreased when combined with Elvitegravir.
Ergotamine
The metabolism of Canagliflozin can be decreased when combined with Ergotamine.
Etoposide
The serum concentration of Etoposide can be increased when it is combined with Canagliflozin.
Gemcitabine
The serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.
Imipramine
The serum concentration of Imipramine can be increased when it is combined with Canagliflozin.
Indinavir
The metabolism of Canagliflozin can be decreased when combined with Indinavir.
Iomeprol
The risk or severity of lactic acidosis can be increased when Iomeprol is combined with Metformin.
Itraconazole
The metabolism of Canagliflozin can be decreased when combined with Itraconazole.
Ketoconazole
The metabolism of Canagliflozin can be decreased when combined with Ketoconazole.
Levoketoconazole
The metabolism of Canagliflozin can be decreased when combined with Levoketoconazole.
Lonafarnib
The metabolism of Canagliflozin can be decreased when combined with Lonafarnib.
Lopinavir
The metabolism of Canagliflozin can be decreased when combined with Lopinavir.
Methimazole
The metabolism of Canagliflozin can be decreased when combined with Methimazole.
Midostaurin
The metabolism of Canagliflozin can be decreased when combined with Midostaurin.
Mitotane
The metabolism of Canagliflozin can be increased when combined with Mitotane.
Nefazodone
The metabolism of Canagliflozin can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Canagliflozin can be decreased when combined with Nelfinavir.
Nilotinib
The metabolism of Canagliflozin can be decreased when combined with Nilotinib.
Nortriptyline
The serum concentration of Nortriptyline can be increased when it is combined with Canagliflozin.
Osimertinib
The serum concentration of Osimertinib can be increased when it is combined with Canagliflozin.
Panobinostat
The serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.
Pomalidomide
The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.
Posaconazole
The metabolism of Canagliflozin can be decreased when combined with Posaconazole.
Procainamide
The excretion of Procainamide can be decreased when combined with Metformin.
Quinidine
The serum concentration of Quinidine can be increased when it is combined with Canagliflozin.
Regorafenib
The serum concentration of Regorafenib can be increased when it is combined with Canagliflozin.
Ribociclib
The metabolism of Canagliflozin can be decreased when combined with Ribociclib.
Rifapentine
The metabolism of Canagliflozin can be increased when combined with Rifapentine.
Rimegepant
The serum concentration of Rimegepant can be increased when it is combined with Canagliflozin.
Romidepsin
The serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.
Saquinavir
The metabolism of Canagliflozin can be decreased when combined with Saquinavir.
Silodosin
The excretion of Silodosin can be decreased when combined with Canagliflozin.
Sirolimus
The serum concentration of Sirolimus can be increased when it is combined with Canagliflozin.
Spironolactone
The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Spironolactone.
Telithromycin
The metabolism of Canagliflozin can be decreased when combined with Telithromycin.
Temsirolimus
The serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.
Tepotinib
The serum concentration of Tepotinib can be increased when it is combined with Canagliflozin.
Tipranavir
The metabolism of Canagliflozin can be decreased when combined with Tipranavir.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Canagliflozin.
Topotecan
The excretion of Topotecan can be decreased when combined with Metformin.
Trastuzumab emtansine
The serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.
Trimipramine
The serum concentration of Trimipramine can be increased when it is combined with Canagliflozin.
Venetoclax
The serum concentration of Venetoclax can be increased when it is combined with Canagliflozin.
Vinblastine
The serum concentration of Vinblastine can be increased when it is combined with Canagliflozin.
Voriconazole
The metabolism of Canagliflozin can be decreased when combined with Voriconazole.
Abrocitinib
The serum concentration of Canagliflozin can be increased when it is combined with Abrocitinib.
Acarbose
Canagliflozin may increase the hypoglycemic activities of Acarbose.
Acebutolol
The therapeutic efficacy of Metformin can be increased when used in combination with Acebutolol.
Acebutolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acebutolol.
Acetazolamide
The risk or severity of lactic acidosis can be increased when Acetazolamide is combined with Metformin.
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Metformin.
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Canagliflozin.
Acyclovir
The excretion of Acyclovir can be decreased when combined with Metformin.
Adagrasib
The serum concentration of Canagliflozin can be increased when it is combined with Adagrasib.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Canagliflozin.
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Metformin.
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Canagliflozin.
Alogliptin
Canagliflozin may increase the hypoglycemic activities of Alogliptin.
Amantadine
The serum concentration of Amantadine can be increased when it is combined with Metformin.
Ambrisentan
The serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Metformin.
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Canagliflozin.
Amikacin
Metformin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amikacin
Canagliflozin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
The serum concentration of Metformin can be increased when it is combined with Amiloride.
Aminosalicylic acid
Aminosalicylic acid may increase the hypoglycemic activities of Metformin.
Aminosalicylic acid
Aminosalicylic acid may increase the hypoglycemic activities of Canagliflozin.
Amiodarone
The serum concentration of Metformin can be increased when it is combined with Amiodarone.
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Metformin.
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Canagliflozin.
Amlodipine
The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Metformin.
Amlodipine
The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Canagliflozin.
Amobarbital
The serum concentration of Canagliflozin can be decreased when it is combined with Amobarbital.
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Metformin.
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Canagliflozin.
Apalutamide
The serum concentration of Metformin can be increased when it is combined with Apalutamide.
Apalutamide
The serum concentration of Canagliflozin can be decreased when it is combined with Apalutamide.
Apixaban
The serum concentration of Apixaban can be increased when it is combined with Canagliflozin.
Aprepitant
The metabolism of Canagliflozin can be decreased when combined with Aprepitant.
Aripiprazole
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.
Arsenic trioxide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.
Articaine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.
Asciminib
The serum concentration of Canagliflozin can be increased when it is combined with Asciminib.
Asenapine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.
Asunaprevir
The serum concentration of Canagliflozin can be increased when it is combined with Asunaprevir.
Atenolol
The serum concentration of Metformin can be increased when it is combined with Atenolol.
Atenolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Atenolol.
Avanafil
The serum concentration of Avanafil can be increased when it is combined with Canagliflozin.
Azilsartan medoxomil
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Azilsartan medoxomil.
Baclofen
The therapeutic efficacy of Metformin can be decreased when used in combination with Baclofen.
Baclofen
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Baclofen.
Balsalazide
Balsalazide may increase the hypoglycemic activities of Metformin.
Balsalazide
Balsalazide may increase the hypoglycemic activities of Canagliflozin.
Baricitinib
The excretion of Baricitinib can be decreased when combined with Metformin.
Beclomethasone dipropionate
The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Canagliflozin.
Belinostat
The serum concentration of Belinostat can be increased when it is combined with Canagliflozin.
Belumosudil
The serum concentration of Canagliflozin can be increased when it is combined with Belumosudil.
Benazepril
The risk or severity of hypoglycemia can be increased when Benazepril is combined with Metformin.
Benazepril
The risk or severity of hypoglycemia can be increased when Benazepril is combined with Canagliflozin.
Bendroflumethiazide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.
Berotralstat
The serum concentration of Berotralstat can be increased when it is combined with Canagliflozin.
Betamethasone
The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Canagliflozin.
Betaxolol
The therapeutic efficacy of Metformin can be increased when used in combination with Betaxolol.
Betaxolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Betaxolol.
Betrixaban
The serum concentration of Betrixaban can be increased when it is combined with Canagliflozin.
Bexagliflozin
Bexagliflozin may increase the hypoglycemic activities of Metformin.
Bexagliflozin
Canagliflozin may increase the hypoglycemic activities of Bexagliflozin.
Bismuth subsalicylate
Bismuth subsalicylate may increase the hypoglycemic activities of Metformin.
Bismuth subsalicylate
Bismuth subsalicylate may increase the hypoglycemic activities of Canagliflozin.
Bisoprolol
The therapeutic efficacy of Metformin can be increased when used in combination with Bisoprolol.
Bisoprolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bisoprolol.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.
Brentuximab vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.
Brexpiprazole
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.
Brigatinib
The excretion of Metformin can be decreased when combined with Brigatinib.
Bromocriptine
The risk or severity of hypoglycemia can be increased when Metformin is combined with Bromocriptine.
Bromocriptine
Canagliflozin may increase the hypoglycemic activities of Bromocriptine.
Budesonide
The risk or severity of hyperglycemia can be increased when Budesonide is combined with Metformin.
Budesonide
The risk or severity of hyperglycemia can be increased when Budesonide is combined with Canagliflozin.
Bumetanide
The risk or severity of hypotension can be increased when Canagliflozin is combined with Bumetanide.
Bupropion
The excretion of Metformin can be decreased when combined with Bupropion.
Butalbital
The serum concentration of Canagliflozin can be decreased when it is combined with Butalbital.
Candesartan cilexetil
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Candesartan cilexetil.
Cannabidiol
The metabolism of Canagliflozin can be decreased when combined with Cannabidiol.
Capivasertib
The serum concentration of Metformin can be increased when it is combined with Capivasertib.
Capmatinib
The excretion of Metformin can be decreased when combined with Capmatinib.
Capmatinib
The serum concentration of Canagliflozin can be increased when it is combined with Capmatinib.
Capreomycin
Metformin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capreomycin
Canagliflozin may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Captopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Captopril.
Carbamazepine
Metformin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Carbamazepine
The metabolism of Canagliflozin can be increased when combined with Carbamazepine.
Carvedilol
The therapeutic efficacy of Metformin can be increased when used in combination with Carvedilol.
Carvedilol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Carvedilol.
Cenobamate
The serum concentration of Canagliflozin can be decreased when it is combined with Cenobamate.
Cephalexin
Cephalexin may decrease the excretion rate of Metformin which could result in a higher serum level.
Chlorothiazide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.
Chlorpheniramine
The serum concentration of Metformin can be increased when it is combined with Chlorpheniramine.
Chlorpromazine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorpromazine.
Chlorthalidone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.
Choline
The serum concentration of Metformin can be increased when it is combined with Choline.
Choline salicylate
Choline salicylate may increase the hypoglycemic activities of Metformin.
Choline salicylate
Choline salicylate may increase the hypoglycemic activities of Canagliflozin.
Ciclesonide
The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Canagliflozin.
Ciprofloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Ciprofloxacin.
Ciprofloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ciprofloxacin.
Cisplatin
Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Citalopram
The risk or severity of hypoglycemia can be increased when Citalopram is combined with Metformin.
Citalopram
The risk or severity of hypoglycemia can be increased when Citalopram is combined with Canagliflozin.
Clevidipine
The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Metformin.
Clevidipine
The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Canagliflozin.
Clobazam
The serum concentration of Clobazam can be increased when it is combined with Canagliflozin.
Clobetasol propionate
The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Canagliflozin.
Clocortolone
The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Metformin.
Clocortolone
The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Canagliflozin.
Clomifene
The serum concentration of Clomifene can be increased when it is combined with Canagliflozin.
Clomipramine
Clomipramine may decrease the hypoglycemic activities of Metformin.
Clomipramine
Clomipramine may decrease the hypoglycemic activities of Canagliflozin.
Clopidogrel
The serum concentration of Metformin can be increased when it is combined with Clopidogrel.
Clozapine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.
Cobicistat
The serum concentration of Canagliflozin can be increased when it is combined with Cobicistat.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Canagliflozin.
Colistin
Metformin may decrease the excretion rate of Colistin which could result in a higher serum level.
Colistin
Canagliflozin may decrease the excretion rate of Colistin which could result in a higher serum level.
Conjugated estrogens
The therapeutic efficacy of Metformin can be decreased when used in combination with Conjugated estrogens.
Conjugated estrogens
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Conjugated estrogens.
Corticotropin
The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Canagliflozin.
Cortisone acetate
The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Canagliflozin.
Crizotinib
The serum concentration of Metformin can be increased when it is combined with Crizotinib.
Dabigatran etexilate
The serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.
Dabrafenib
The serum concentration of Canagliflozin can be decreased when it is combined with Dabrafenib.
Danicopan
The serum concentration of Canagliflozin can be increased when it is combined with Danicopan.
Dapagliflozin
Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.
Daptomycin
The serum concentration of Daptomycin can be increased when it is combined with Canagliflozin.
Darolutamide
The serum concentration of Darolutamide can be increased when it is combined with Canagliflozin.
Dasabuvir
The serum concentration of Dasabuvir can be increased when it is combined with Canagliflozin.
Deferasirox
The metabolism of Canagliflozin can be decreased when combined with Deferasirox.
Deflazacort
The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Canagliflozin.
Delafloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Delafloxacin.
Delafloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Delafloxacin.
Desipramine
Desipramine may decrease the hypoglycemic activities of Metformin.
Desipramine
Desipramine may decrease the hypoglycemic activities of Canagliflozin.
Desogestrel
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.
Desonide
The risk or severity of hyperglycemia can be increased when Desonide is combined with Metformin.
Desonide
The risk or severity of hyperglycemia can be increased when Desonide is combined with Canagliflozin.
Desoximetasone
The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Metformin.
Desoximetasone
The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Canagliflozin.
Desvenlafaxine
The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Metformin.
Desvenlafaxine
The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Canagliflozin.
Deutivacaftor
The serum concentration of Canagliflozin can be increased when it is combined with Deutivacaftor.
Dexamethasone
The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Canagliflozin.
Dexamethasone acetate
The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Metformin.
Dexamethasone acetate
The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Canagliflozin.
Dexchlorpheniramine maleate
The serum concentration of Metformin can be increased when it is combined with Dexchlorpheniramine maleate.
Diazoxide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.
Diclofenamide
The risk or severity of lactic acidosis can be increased when Diclofenamide is combined with Metformin.
Dienogest
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.
Diflorasone
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Metformin.
Diflorasone
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Canagliflozin.
Diflunisal
Diflunisal may increase the hypoglycemic activities of Metformin.
Diflunisal
Diflunisal may increase the hypoglycemic activities of Canagliflozin.
Difluprednate
The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Metformin.
Difluprednate
The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Canagliflozin.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Metformin.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Canagliflozin.
Diltiazem
The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Metformin.
Diltiazem
The metabolism of Canagliflozin can be decreased when combined with Diltiazem.
Dinoprostone
The serum concentration of Metformin can be increased when it is combined with Dinoprostone.
Diosmin
The serum concentration of Canagliflozin can be increased when it is combined with Diosmin.
Diphenhydramine
The serum concentration of Metformin can be increased when it is combined with Diphenhydramine.
Dipotassium phosphate
Dipotassium phosphate may increase the hyperkalemic activities of Canagliflozin.
Disopyramide
The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Metformin.
Disopyramide
Canagliflozin may increase the hypoglycemic activities of Disopyramide.
Dofetilide
The serum concentration of Dofetilide can be increased when it is combined with Metformin.
Dolutegravir
The serum concentration of Metformin can be increased when it is combined with Dolutegravir.
Dolutegravir
The serum concentration of Dolutegravir can be increased when it is combined with Canagliflozin.
Dopamine
The serum concentration of Dopamine can be increased when it is combined with Metformin.
Doxepin
Doxepin may decrease the hypoglycemic activities of Metformin.
Doxepin
Doxepin may decrease the hypoglycemic activities of Canagliflozin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.
Dronedarone
The serum concentration of Metformin can be increased when it is combined with Dronedarone.
Dronedarone
The metabolism of Canagliflozin can be decreased when combined with Dronedarone.
Drospirenone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.
Dulaglutide
The risk or severity of hypoglycemia can be increased when Metformin is combined with Dulaglutide.
Dulaglutide
Canagliflozin may increase the hypoglycemic activities of Dulaglutide.
Duloxetine
The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Metformin.
Duvelisib
The serum concentration of Duvelisib can be increased when it is combined with Canagliflozin.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.
Efavirenz
The serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.
Elacestrant
The serum concentration of Canagliflozin can be increased when it is combined with Elacestrant.
Elagolix
The serum concentration of Elagolix can be increased when it is combined with Canagliflozin.
Elbasvir
The serum concentration of Elbasvir can be increased when it is combined with Canagliflozin.
Eliglustat
The serum concentration of Canagliflozin can be increased when it is combined with Eliglustat.
Eltrombopag
The metabolism of Canagliflozin can be decreased when combined with Eltrombopag.
Empagliflozin
Canagliflozin may increase the hypoglycemic activities of Empagliflozin.
Enalapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalapril.
Enalaprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Enalaprilat.
Enasidenib
The serum concentration of Metformin can be increased when it is combined with Enasidenib.
Enasidenib
The serum concentration of Canagliflozin can be increased when it is combined with Enasidenib.
Encorafenib
The serum concentration of Metformin can be increased when it is combined with Encorafenib.
Encorafenib
The serum concentration of Encorafenib can be increased when it is combined with Canagliflozin.
Enfortumab vedotin
The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin.
Entrectinib
The serum concentration of Canagliflozin can be increased when it is combined with Entrectinib.
Enzalutamide
The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.
Epcoritamab
The serum concentration of Canagliflozin can be increased when it is combined with Epcoritamab.
Epinephrine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.
Eprosartan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Eprosartan.
Erdafitinib
The serum concentration of Metformin can be increased when it is combined with Erdafitinib.
Erdafitinib
The serum concentration of Canagliflozin can be increased when it is combined with Erdafitinib.
Ertugliflozin
Canagliflozin may increase the hypoglycemic activities of Ertugliflozin.
Erythromycin
The serum concentration of Canagliflozin can be increased when it is combined with Erythromycin.
Escitalopram
The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Metformin.
Escitalopram
The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Canagliflozin.
Estetrol
The therapeutic efficacy of Metformin can be decreased when used in combination with Estetrol.
Estetrol
The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Estetrol.
Estradiol
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estradiol.
Estradiol acetate
The serum concentration of Metformin can be increased when it is combined with Estradiol acetate.
Estradiol cypionate
The serum concentration of Metformin can be increased when it is combined with Estradiol cypionate.
Estradiol valerate
The serum concentration of Metformin can be increased when it is combined with Estradiol valerate.
Estrone sulfate
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estrone sulfate.
Etacrynic acid
The risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.
Ethanol
Ethanol may increase the hypotensive activities of Canagliflozin.
Ethinylestradiol
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinylestradiol.
Ethosuximide
The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Metformin.
Ethosuximide
The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Canagliflozin.
Ethynodiol diacetate
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.
Etonogestrel
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Canagliflozin.
Exenatide
The risk or severity of hypoglycemia can be increased when Exenatide is combined with Metformin.
Exenatide
Canagliflozin may increase the hypoglycemic activities of Exenatide.
Famotidine
The serum concentration of Metformin can be increased when it is combined with Famotidine.
Fedratinib
Fedratinib may decrease the excretion rate of Metformin which could result in a higher serum level.
Fedratinib
The serum concentration of Canagliflozin can be increased when it is combined with Fedratinib.
Felodipine
The risk or severity of hypoglycemia can be increased when Felodipine is combined with Metformin.
Felodipine
The risk or severity of hypoglycemia can be increased when Felodipine is combined with Canagliflozin.
Fexinidazole
The serum concentration of Metformin can be increased when it is combined with Fexinidazole.
Fexofenadine
The serum concentration of Fexofenadine can be increased when it is combined with Canagliflozin.
Flibanserin
The serum concentration of Canagliflozin can be increased when it is combined with Flibanserin.
Fluconazole
The risk or severity of hypoglycemia can be increased when Metformin is combined with Fluconazole.
Fluconazole
The risk or severity of hypoglycemia can be increased when Canagliflozin is combined with Fluconazole.
Fludrocortisone
The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Canagliflozin.
Flunisolide
The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Metformin.
Flunisolide
The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Canagliflozin.
Fluocinolone acetonide
The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Metformin.
Fluocinolone acetonide
The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Canagliflozin.
Fluocinonide
The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Metformin.
Fluocinonide
The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Canagliflozin.
Fluorometholone
The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Canagliflozin.
Fluoxetine
The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Metformin.
Fluoxetine
The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Canagliflozin.
Flurandrenolide
The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Metformin.
Flurandrenolide
The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Canagliflozin.
Flurazepam
The serum concentration of Metformin can be increased when it is combined with Flurazepam.
Fluticasone furoate
The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Canagliflozin.
Fluticasone propionate
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Metformin.
Fluticasone propionate
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Canagliflozin.
Fluvoxamine
The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Metformin.
Fluvoxamine
The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Canagliflozin.
Fosamprenavir
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.
Fosinopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.
Fosnetupitant
The metabolism of Canagliflozin can be decreased when combined with Fosnetupitant.
Fosphenytoin
The serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.
Fostemsavir
The serum concentration of Fostemsavir can be increased when it is combined with Canagliflozin.
Furosemide
The risk or severity of hypotension can be increased when Canagliflozin is combined with Furosemide.
Fusidic acid
The metabolism of Canagliflozin can be decreased when combined with Fusidic acid.
Futibatinib
The serum concentration of Futibatinib can be increased when it is combined with Canagliflozin.
Ganciclovir
The excretion of Ganciclovir can be decreased when combined with Metformin.
Gatifloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Gatifloxacin.
Gatifloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gatifloxacin.
Gemifloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Gemifloxacin.
Gemifloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Gemifloxacin.
Gentamicin
Metformin may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gentamicin
Canagliflozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gilteritinib
The serum concentration of Gilteritinib can be increased when it is combined with Canagliflozin.
Glasdegib
The excretion of Metformin can be decreased when combined with Glasdegib.
Glasdegib
The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin.
Glecaprevir
The serum concentration of Glecaprevir can be increased when it is combined with Canagliflozin.
Glimepiride
Canagliflozin may increase the hypoglycemic activities of Glimepiride.
Glipizide
Canagliflozin may increase the hypoglycemic activities of Glipizide.
Glofitamab
The serum concentration of Canagliflozin can be increased when it is combined with Glofitamab.
Glyburide
Canagliflozin may increase the hypoglycemic activities of Glyburide.
Goserelin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.
Grazoprevir
The serum concentration of Grazoprevir can be increased when it is combined with Canagliflozin.
Guanidine
The serum concentration of Metformin can be increased when it is combined with Guanidine.
Halcinonide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Metformin.
Halcinonide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Canagliflozin.
Haloperidol
The serum concentration of Haloperidol can be increased when it is combined with Canagliflozin.
Histamine
The serum concentration of Histamine can be increased when it is combined with Metformin.
Histrelin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.
Hydrochlorothiazide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.
Hydrocortisone
The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Canagliflozin.
Hydrocortisone acetate
The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Metformin.
Hydrocortisone acetate
The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Canagliflozin.
Hydrocortisone butyrate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Metformin.
Hydrocortisone butyrate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Canagliflozin.
Hydrocortisone probutate
The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Metformin.
Hydrocortisone probutate
The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Canagliflozin.
Hydrocortisone succinate
The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Metformin.
Hydrocortisone succinate
The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Canagliflozin.
Hydrocortisone valerate
The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Metformin.
Hydrocortisone valerate
The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Canagliflozin.
Hydroflumethiazide
The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide.
Hydroflumethiazide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroflumethiazide.
Hydroxychloroquine
The therapeutic efficacy of Metformin can be increased when used in combination with Hydroxychloroquine.
Hydroxychloroquine
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Hydroxychloroquine.
Hydroxyprogesterone caproate
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.
Idelalisib
The serum concentration of Idelalisib can be increased when it is combined with Canagliflozin.
Iloperidone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.
Imatinib
The serum concentration of Metformin can be increased when it is combined with Imatinib.
Imipramine
Imipramine may decrease the hypoglycemic activities of Metformin.
Indapamide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.
Indomethacin
The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Metformin.
Indomethacin
The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Canagliflozin.
Insulin aspart
The risk or severity of adverse effects can be increased when Insulin aspart is combined with Metformin.
Insulin aspart
The risk or severity of hypoglycemia can be increased when Insulin aspart is combined with Canagliflozin.
Insulin degludec
The risk or severity of adverse effects can be increased when Insulin degludec is combined with Metformin.
Insulin degludec
The risk or severity of hypoglycemia can be increased when Insulin degludec is combined with Canagliflozin.
Insulin detemir
The risk or severity of adverse effects can be increased when Insulin detemir is combined with Metformin.
Insulin detemir
The risk or severity of hypoglycemia can be increased when Insulin detemir is combined with Canagliflozin.
Insulin glargine
The risk or severity of adverse effects can be increased when Insulin glargine is combined with Metformin.
Insulin glargine
The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Canagliflozin.
Insulin glulisine
The risk or severity of adverse effects can be increased when Insulin glulisine is combined with Metformin.
Insulin glulisine
The risk or severity of hypoglycemia can be increased when Insulin glulisine is combined with Canagliflozin.
Insulin human
The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin.
Insulin human
The risk or severity of hypoglycemia can be increased when Insulin human is combined with Canagliflozin.
Insulin lispro
The risk or severity of adverse effects can be increased when Insulin lispro is combined with Metformin.
Insulin lispro
The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Canagliflozin.
Iodixanol
The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin.
Iohexol
The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin.
Iopamidol
The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin.
Iopromide
The risk or severity of lactic acidosis can be increased when Iopromide is combined with Metformin.
Ioversol
The risk or severity of adverse effects can be increased when Ioversol is combined with Metformin.
Irbesartan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Irbesartan.
Isavuconazonium
The serum concentration of Metformin can be increased when it is combined with Isavuconazonium.
Isavuconazonium
The serum concentration of Canagliflozin can be increased when it is combined with Isavuconazonium.
Isocarboxazid
Isocarboxazid may increase the orthostatic hypotensive activities of Canagliflozin.
Isoniazid
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Isoniazid.
Isradipine
The risk or severity of hypoglycemia can be increased when Isradipine is combined with Metformin.
Isradipine
The metabolism of Canagliflozin can be decreased when combined with Isradipine.
Istradefylline
The excretion of Metformin can be decreased when combined with Istradefylline.
Istradefylline
The serum concentration of Canagliflozin can be increased when it is combined with Istradefylline.
Ivacaftor
The serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.
Ivosidenib
The metabolism of Canagliflozin can be increased when combined with Ivosidenib.
Ixabepilone
The serum concentration of Canagliflozin can be increased when it is combined with Ixabepilone.
Labetalol
The therapeutic efficacy of Metformin can be increased when used in combination with Labetalol.
Labetalol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Labetalol.
Lanreotide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.
Lapatinib
The serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.
Lasmiditan
The serum concentration of Canagliflozin can be increased when it is combined with Lasmiditan.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Canagliflozin.
Lefamulin
Canagliflozin may decrease the excretion rate of Lefamulin which could result in a higher serum level.
Lemborexant
The serum concentration of Lemborexant can be increased when it is combined with Canagliflozin.
Lenacapavir
The serum concentration of Lenacapavir can be increased when it is combined with Canagliflozin.
Lenvatinib
The serum concentration of Metformin can be increased when it is combined with Lenvatinib.
Lenvatinib
The serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.
Leuprolide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.
Levamlodipine
The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Metformin.
Levamlodipine
The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Canagliflozin.
Levofloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Levofloxacin.
Levofloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.
Levoketoconazole
The serum concentration of Metformin can be increased when it is combined with Levoketoconazole.
Levomilnacipran
The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Metformin.
Levomilnacipran
The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Canagliflozin.
Levonorgestrel
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.
Levothyroxine
The therapeutic efficacy of Metformin can be decreased when used in combination with Levothyroxine.
Linagliptin
Canagliflozin may increase the hypoglycemic activities of Linagliptin.
Linezolid
Linezolid may increase the orthostatic hypotensive activities of Canagliflozin.
Liothyronine
The therapeutic efficacy of Metformin can be decreased when used in combination with Liothyronine.
Liothyronine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Liothyronine.
Lipoic acid
The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Canagliflozin.
Liraglutide
The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Metformin.
Liraglutide
Canagliflozin may increase the hypoglycemic activities of Liraglutide.
Lisinopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Lisinopril.
Lixisenatide
The risk or severity of hypoglycemia can be increased when Metformin is combined with Lixisenatide.
Lixisenatide
Canagliflozin may increase the hypoglycemic activities of Lixisenatide.
Lomefloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Lomefloxacin.
Lomefloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Lomefloxacin.
Lomitapide
The serum concentration of Canagliflozin can be increased when it is combined with Lomitapide.
Lonapegsomatropin
The therapeutic efficacy of Metformin can be decreased when used in combination with Lonapegsomatropin.
Lonapegsomatropin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lonapegsomatropin.
Loncastuximab tesirine
The serum concentration of Loncastuximab tesirine can be increased when it is combined with Canagliflozin.
Losartan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Losartan.
Loxapine
The serum concentration of Canagliflozin can be increased when it is combined with Loxapine.
Lumacaftor
The serum concentration of Canagliflozin can be decreased when it is combined with Lumacaftor.
Lurasidone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.
Lusutrombopag
The serum concentration of Lusutrombopag can be increased when it is combined with Canagliflozin.
Magnesium sulfate
The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Metformin.
Magnesium sulfate
The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Canagliflozin.
Mannitol
The serum concentration of Mannitol can be increased when it is combined with Canagliflozin.
Maribavir
The serum concentration of Canagliflozin can be increased when it is combined with Maribavir.
Mavacamten
The serum concentration of Canagliflozin can be decreased when it is combined with Mavacamten.
Mavorixafor
The excretion of Mavorixafor can be decreased when combined with Canagliflozin.
Mecasermin
The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Metformin.
Mecasermin
Canagliflozin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetate
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
Medrysone
The risk or severity of hyperglycemia can be increased when Medrysone is combined with Metformin.
Medrysone
The risk or severity of hyperglycemia can be increased when Medrysone is combined with Canagliflozin.
Mefenamic acid
The metabolism of Canagliflozin can be decreased when combined with Mefenamic acid.
Mefloquine
The serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.
Megestrol acetate
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Megestrol acetate.
Mesalazine
Mesalazine may increase the hypoglycemic activities of Metformin.
Mesalazine
Mesalazine may increase the hypoglycemic activities of Canagliflozin.
Methazolamide
The risk or severity of lactic acidosis can be increased when Methazolamide is combined with Metformin.
Methohexital
The serum concentration of Canagliflozin can be decreased when it is combined with Methohexital.
Methsuximide
The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Metformin.
Methsuximide
The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Canagliflozin.
Methyl salicylate
Methyl salicylate may increase the hypoglycemic activities of Metformin.
Methyl salicylate
Methyl salicylate may increase the hypoglycemic activities of Canagliflozin.
Methylene blue
The serum concentration of Metformin can be increased when it is combined with Methylene blue.
Methylene blue
Methylene blue may increase the orthostatic hypotensive activities of Canagliflozin.
Methylprednisolone
The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Canagliflozin.
Methylprednisolone hemisuccinate
The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Metformin.
Methylprednisolone hemisuccinate
The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Canagliflozin.
Metolazone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.
Metoprolol
The therapeutic efficacy of Metformin can be increased when used in combination with Metoprolol.
Metoprolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Metoprolol.
Miconazole
The metabolism of Canagliflozin can be decreased when combined with Miconazole.
Midazolam
The serum concentration of Midazolam can be increased when it is combined with Canagliflozin.
Mifepristone
The risk or severity of hypoglycemia can be increased when Mifepristone is combined with Metformin.
Mifepristone
Canagliflozin may increase the hypoglycemic activities of Mifepristone.
Miglitol
Canagliflozin may increase the hypoglycemic activities of Miglitol.
Milnacipran
The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Metformin.
Milnacipran
The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Canagliflozin.
Mirabegron
The serum concentration of Canagliflozin can be increased when it is combined with Mirabegron.
Mitapivat
The serum concentration of Canagliflozin can be increased when it is combined with Mitapivat.
Moexipril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Moexipril.
Mometasone furoate
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Canagliflozin.
Monopotassium phosphate
Monopotassium phosphate may increase the hyperkalemic activities of Canagliflozin.
Morphine
The serum concentration of Morphine can be increased when it is combined with Canagliflozin.
Moxifloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.
Moxifloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.
Nadolol
The therapeutic efficacy of Metformin can be increased when used in combination with Nadolol.
Nadolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nadolol.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.
Nateglinide
Canagliflozin may increase the hypoglycemic activities of Nateglinide.
Nebivolol
The therapeutic efficacy of Metformin can be increased when used in combination with Nebivolol.
Nebivolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nebivolol.
Nefazodone
The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Metformin.
Neomycin
Metformin may decrease the excretion rate of Neomycin which could result in a higher serum level.
Neomycin
Canagliflozin may decrease the excretion rate of Neomycin which could result in a higher serum level.
Neratinib
The serum concentration of Canagliflozin can be increased when it is combined with Neratinib.
Netupitant
The metabolism of Canagliflozin can be decreased when combined with Netupitant.
Niacin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.
Nicardipine
The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Metformin.
Nicardipine
The metabolism of Canagliflozin can be decreased when combined with Nicardipine.
Nicotine
The serum concentration of Metformin can be increased when it is combined with Nicotine.
Nifedipine
The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Metformin.
Nifedipine
The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Canagliflozin.
Nimodipine
The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Metformin.
Nimodipine
The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Canagliflozin.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.
Nirogacestat
The serum concentration of Nirogacestat can be increased when it is combined with Canagliflozin.
Nisoldipine
The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Metformin.
Nisoldipine
The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Canagliflozin.
Norepinephrine
The serum concentration of Norepinephrine can be increased when it is combined with Metformin.
Norethisterone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.
Norgestimate
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norgestimate.
Nortriptyline
Nortriptyline may decrease the hypoglycemic activities of Metformin.
Octreotide
The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.
Octreotide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.
Ofloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Ofloxacin.
Ofloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ofloxacin.
Olanzapine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.
Olmesartan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Olmesartan.
Olsalazine
Olsalazine may increase the hypoglycemic activities of Metformin.
Olsalazine
Olsalazine may increase the hypoglycemic activities of Canagliflozin.
Omadacycline
The serum concentration of Omadacycline can be increased when it is combined with Canagliflozin.
Ombitasvir
The serum concentration of Ombitasvir can be increased when it is combined with Canagliflozin.
Pacritinib
The serum concentration of Canagliflozin can be increased when it is combined with Pacritinib.
Palbociclib
The serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.
Paliperidone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.
Paritaprevir
The serum concentration of Paritaprevir can be increased when it is combined with Canagliflozin.
Paroxetine
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Metformin.
Paroxetine
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.
Pasireotide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.
Patiromer
Patiromer can cause a decrease in the absorption of Metformin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.
Pegvisomant
The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Metformin.
Pegvisomant
The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Canagliflozin.
Pemetrexed
Metformin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Pemetrexed
Canagliflozin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Pentamidine
Canagliflozin may increase the hypoglycemic activities of Pentamidine.
Pentobarbital
The serum concentration of Canagliflozin can be decreased when it is combined with Pentobarbital.
Pentostatin
Metformin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Pentostatin
Canagliflozin may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Perindopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Perindopril.
Pexidartinib
The excretion of Metformin can be decreased when combined with Pexidartinib.
Phenelzine
Phenelzine may increase the orthostatic hypotensive activities of Canagliflozin.
Phenobarbital
The serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.
Phenoxybenzamine
The serum concentration of Metformin can be increased when it is combined with Phenoxybenzamine.
Phentermine
The therapeutic efficacy of Metformin can be increased when used in combination with Phentermine.
Phentermine
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Phentermine.
Phenytoin
The serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.
Pibrentasvir
The serum concentration of Pibrentasvir can be increased when it is combined with Canagliflozin.
Pinaverium
The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Metformin.
Pinaverium
The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Canagliflozin.
Pindolol
The therapeutic efficacy of Metformin can be increased when used in combination with Pindolol.
Pindolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pindolol.
Pioglitazone
Canagliflozin may increase the hypoglycemic activities of Pioglitazone.
Piperine
The serum concentration of Canagliflozin can be increased when it is combined with Piperine.
Pirtobrutinib
The serum concentration of Canagliflozin can be increased when it is combined with Pirtobrutinib.
Pitolisant
The serum concentration of Canagliflozin can be decreased when it is combined with Pitolisant.
Plazomicin
Metformin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plazomicin
Canagliflozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polythiazide
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.
Ponatinib
The serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.
Potassium
Potassium may increase the hyperkalemic activities of Canagliflozin.
Potassium acetate
Potassium acetate may increase the hyperkalemic activities of Canagliflozin.
Potassium bicarbonate
Potassium bicarbonate may increase the hyperkalemic activities of Canagliflozin.
Potassium bitartrate
Potassium bitartrate may increase the hyperkalemic activities of Canagliflozin.
Potassium carbonate
Potassium carbonate may increase the hyperkalemic activities of Canagliflozin.
Potassium cation
Potassium cation may increase the hyperkalemic activities of Canagliflozin.
Potassium chloride
Potassium chloride may increase the hyperkalemic activities of Canagliflozin.
Potassium citrate
Potassium citrate may increase the hyperkalemic activities of Canagliflozin.
Potassium hydroxide
Potassium hydroxide may increase the hyperkalemic activities of Canagliflozin.
Potassium Iodide
Potassium Iodide may increase the hyperkalemic activities of Canagliflozin.
Potassium nitrate
Potassium nitrate may increase the hyperkalemic activities of Canagliflozin.
Potassium permanganate
Potassium permanganate may increase the hyperkalemic activities of Canagliflozin.
Potassium sulfate
Potassium sulfate may increase the hyperkalemic activities of Canagliflozin.
Potassium triiodide
Potassium triiodide may increase the hyperkalemic activities of Canagliflozin.
Pralsetinib
The excretion of Metformin can be decreased when combined with Pralsetinib.
Pralsetinib
The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin.
Pramlintide
The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Metformin.
Pramlintide
Canagliflozin may increase the hypoglycemic activities of Pramlintide.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Canagliflozin.
Prednicarbate
The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Metformin.
Prednicarbate
The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Canagliflozin.
Prednisolone
The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Canagliflozin.
Prednisolone acetate
The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Metformin.
Prednisolone acetate
The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Canagliflozin.
Prednisolone phosphate
The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Metformin.
Prednisolone phosphate
The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Canagliflozin.
Prednisone
The risk or severity of hyperglycemia can be increased when Prednisone is combined with Canagliflozin.
Pregabalin
The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Metformin.
Pregabalin
The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Canagliflozin.
Pretomanid
The serum concentration of Canagliflozin can be increased when it is combined with Pretomanid.
Primaquine
The metabolism of Canagliflozin can be decreased when combined with Primaquine.
Primidone
The serum concentration of Canagliflozin can be decreased when it is combined with Primidone.
Probenecid
The serum concentration of Metformin can be increased when it is combined with Probenecid.
Procainamide
Canagliflozin may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine
Procaine may increase the orthostatic hypotensive activities of Canagliflozin.
Procarbazine
Procarbazine may increase the orthostatic hypotensive activities of Canagliflozin.
Progesterone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.
Propafenone
The therapeutic efficacy of Metformin can be increased when used in combination with Propafenone.
Propafenone
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propafenone.
Propranolol
The therapeutic efficacy of Metformin can be increased when used in combination with Propranolol.
Propranolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Propranolol.
Protriptyline
Protriptyline may decrease the hypoglycemic activities of Metformin.
Protriptyline
Protriptyline may decrease the hypoglycemic activities of Canagliflozin.
Prucalopride
The serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.
Pseudoephedrine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pseudoephedrine.
Pyrimethamine
The excretion of Metformin can be decreased when combined with Pyrimethamine.
Quetiapine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.
Quinapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Quinapril.
Quinidine
Metformin may decrease the excretion rate of Quinidine which could result in a higher serum level.
Quinine
The risk or severity of hypoglycemia can be increased when Quinine is combined with Metformin.
Quinine
Canagliflozin may increase the hypoglycemic activities of Quinine.
Quizartinib
The serum concentration of Quizartinib can be increased when it is combined with Canagliflozin.
Ramipril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Ramipril.
Ranitidine
The serum concentration of Ranitidine can be increased when it is combined with Metformin.
Ranolazine
The serum concentration of Metformin can be increased when it is combined with Ranolazine.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.
Rasagiline
Rasagiline may increase the orthostatic hypotensive activities of Canagliflozin.
Relebactam
The excretion of Relebactam can be decreased when combined with Metformin.
Relugolix
The serum concentration of Relugolix can be increased when it is combined with Canagliflozin.
Repaglinide
Canagliflozin may increase the hypoglycemic activities of Repaglinide.
Repotrectinib
The excretion of Metformin can be decreased when combined with Repotrectinib.
Repotrectinib
The serum concentration of Repotrectinib can be increased when it is combined with Canagliflozin.
Reserpine
The serum concentration of Canagliflozin can be increased when it is combined with Reserpine.
Revefenacin
The serum concentration of Revefenacin can be increased when it is combined with Canagliflozin.
Rifampin
The serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.
Riociguat
The serum concentration of Riociguat can be increased when it is combined with Canagliflozin.
Ripretinib
The serum concentration of Ripretinib can be increased when it is combined with Canagliflozin.
Risdiplam
The serum concentration of Metformin can be increased when it is combined with Risdiplam.
Ritlecitinib
The serum concentration of Canagliflozin can be increased when it is combined with Ritlecitinib.
Ritonavir
The metabolism of Canagliflozin can be increased when combined with Ritonavir.
Rivaroxaban
The serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.
Rolapitant
The serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.
Rosiglitazone
Canagliflozin may increase the hypoglycemic activities of Rosiglitazone.
Safinamide
Safinamide may increase the orthostatic hypotensive activities of Canagliflozin.
Salicylic acid
Salicylic acid may increase the hypoglycemic activities of Metformin.
Salicylic acid
Salicylic acid may increase the hypoglycemic activities of Canagliflozin.
Salmeterol
The serum concentration of Metformin can be increased when it is combined with Salmeterol.
Sapropterin
The serum concentration of Canagliflozin can be increased when it is combined with Sapropterin.
Sarecycline
The serum concentration of Canagliflozin can be increased when it is combined with Sarecycline.
Satralizumab
The serum concentration of Canagliflozin can be decreased when it is combined with Satralizumab.
Saxagliptin
Canagliflozin may increase the hypoglycemic activities of Saxagliptin.
Secobarbital
The serum concentration of Canagliflozin can be decreased when it is combined with Secobarbital.
Selegiline
Selegiline may increase the orthostatic hypotensive activities of Canagliflozin.
Selexipag
The serum concentration of Selexipag can be increased when it is combined with Canagliflozin.
Selumetinib
The serum concentration of Selumetinib can be increased when it is combined with Canagliflozin.
Semaglutide
The risk or severity of hypoglycemia can be increased when Metformin is combined with Semaglutide.
Semaglutide
Canagliflozin may increase the hypoglycemic activities of Semaglutide.
Sertraline
The risk or severity of hypoglycemia can be increased when Sertraline is combined with Metformin.
Sertraline
The risk or severity of hypoglycemia can be increased when Sertraline is combined with Canagliflozin.
Sildenafil
The serum concentration of Canagliflozin can be increased when it is combined with Sildenafil.
Simvastatin
The serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.
Sitagliptin
Canagliflozin may increase the hypoglycemic activities of Sitagliptin.
Sodium ferric gluconate complex
The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Canagliflozin.
Sodium phosphate, monobasic
Sodium phosphate, monobasic may increase the hyperkalemic activities of Canagliflozin.
Sofosbuvir
The serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.
Somapacitan
The therapeutic efficacy of Metformin can be decreased when used in combination with Somapacitan.
Somapacitan
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somapacitan.
Somatotropin
Somatotropin may decrease the hypoglycemic activities of Metformin.
Somatotropin
Somatotropin may decrease the hypoglycemic activities of Canagliflozin.
Somatrogon
The therapeutic efficacy of Metformin can be decreased when used in combination with Somatrogon.
Somatrogon
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Somatrogon.
Sorafenib
The serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.
Sotagliflozin
The risk or severity of hypoglycemia can be increased when Metformin is combined with Sotagliflozin.
Sotagliflozin
Canagliflozin may increase the hypoglycemic activities of Sotagliflozin.
Sotalol
The risk or severity of hypoglycemia can be increased when Sotalol is combined with Metformin.
Sotalol
The risk or severity of hypoglycemia can be increased when Sotalol is combined with Canagliflozin.
Sotorasib
The serum concentration of Canagliflozin can be decreased when it is combined with Sotorasib.
Sparsentan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Sparsentan.
Stiripentol
The metabolism of Canagliflozin can be decreased when combined with Stiripentol.
Streptomycin
Metformin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptomycin
Canagliflozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sulfadiazine
The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Metformin.
Sulfadiazine
Canagliflozin may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Metformin.
Sulfamethoxazole
Canagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
Sulfasalazine
Sulfasalazine may increase the hypoglycemic activities of Metformin.
Sulfasalazine
Sulfasalazine may increase the hypoglycemic activities of Canagliflozin.
Sunitinib
The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Metformin.
Sunitinib
Canagliflozin may increase the hypoglycemic activities of Sunitinib.
Suvorexant
The serum concentration of Canagliflozin can be increased when it is combined with Suvorexant.
Tacrolimus
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.
Tafenoquine
The serum concentration of Metformin can be increased when it is combined with Tafenoquine.
Taletrectinib
The excretion of Metformin can be decreased when combined with Taletrectinib.
Taletrectinib
The serum concentration of Taletrectinib can be increased when it is combined with Canagliflozin.
Tamoxifen
The serum concentration of Canagliflozin can be increased when it is combined with Tamoxifen.
Tazemetostat
The excretion of Metformin can be decreased when combined with Tazemetostat.
Tazemetostat
The serum concentration of Tazemetostat can be increased when it is combined with Canagliflozin.
Technetium Tc-99m sestamibi
The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Canagliflozin.
Tegaserod
The serum concentration of Tegaserod can be increased when it is combined with Canagliflozin.
Telmisartan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Telmisartan.
Telotristat ethyl
The serum concentration of Canagliflozin can be decreased when it is combined with Telotristat ethyl.
Tenofovir alafenamide
The serum concentration of Tenofovir alafenamide can be increased when it is combined with Metformin.
Tenofovir alafenamide
The serum concentration of Tenofovir alafenamide can be increased when it is combined with Canagliflozin.
Tenofovir disoproxil
The serum concentration of Tenofovir disoproxil can be increased when it is combined with Canagliflozin.
Teprotumumab
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Teprotumumab.
Tezacaftor
The serum concentration of Tezacaftor can be increased when it is combined with Canagliflozin.
Thiamine
The serum concentration of Metformin can be increased when it is combined with Thiamine.
Thyroid, porcine
The therapeutic efficacy of Metformin can be decreased when used in combination with Thyroid, porcine.
Thyroid, porcine
Thyroid, porcine may decrease the hypoglycemic activities of Canagliflozin.
Thyrotropin alfa
The therapeutic efficacy of Metformin can be decreased when used in combination with Thyrotropin alfa.
Thyrotropin alfa
Thyrotropin alfa may decrease the hypoglycemic activities of Canagliflozin.
Ticagrelor
The serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.
Timolol
The therapeutic efficacy of Metformin can be increased when used in combination with Timolol.
Timolol
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Timolol.
Tirzepatide
The risk or severity of hypoglycemia can be increased when Metformin is combined with Tirzepatide.
Tirzepatide
Canagliflozin may increase the hypoglycemic activities of Tirzepatide.
Tivozanib
The serum concentration of Tivozanib can be increased when it is combined with Canagliflozin.
Tixocortol
The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Metformin.
Tixocortol
The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Canagliflozin.
Tobramycin
Metformin may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tobramycin
Canagliflozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tolazamide
The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Metformin.
Tolazamide
Canagliflozin may increase the hypoglycemic activities of Tolazamide.
Topiramate
The risk or severity of lactic acidosis can be increased when Topiramate is combined with Metformin.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Canagliflozin.
Torasemide
The risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide.
Toremifene
The serum concentration of Canagliflozin can be increased when it is combined with Toremifene.
Trandolapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Trandolapril.
Tranylcypromine
Tranylcypromine may increase the orthostatic hypotensive activities of Canagliflozin.
Triamcinolone
The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Canagliflozin.
Trilaciclib
The serum concentration of Metformin can be increased when it is combined with Trilaciclib.
Trilaciclib
The serum concentration of Trilaciclib can be increased when it is combined with Canagliflozin.
Trimethoprim
The serum concentration of Metformin can be increased when it is combined with Trimethoprim.
Trimipramine
Trimipramine may decrease the hypoglycemic activities of Metformin.
Triptorelin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.
Trolamine salicylate
Trolamine salicylate may increase the hypoglycemic activities of Metformin.
Trolamine salicylate
Trolamine salicylate may increase the hypoglycemic activities of Canagliflozin.
Trovafloxacin
The therapeutic efficacy of Metformin can be increased when used in combination with Trovafloxacin.
Trovafloxacin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Trovafloxacin.
Tucatinib
The serum concentration of Metformin can be increased when it is combined with Tucatinib.
Tucatinib
Tucatinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ubidecarenone
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metformin.
Ubidecarenone
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Canagliflozin.
Ubrogepant
The serum concentration of Ubrogepant can be increased when it is combined with Canagliflozin.
Ulobetasol
The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Metformin.
Ulobetasol
The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Canagliflozin.
Umeclidinium
The serum concentration of Umeclidinium can be increased when it is combined with Canagliflozin.
Valsartan
The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Valsartan.
Vamorolone
The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Metformin.
Vamorolone
The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Canagliflozin.
Vancomycin
Metformin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vancomycin
Canagliflozin may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vandetanib
The serum concentration of Metformin can be increased when it is combined with Vandetanib.
Vandetanib
The serum concentration of Canagliflozin can be increased when it is combined with Vandetanib.
Vardenafil
The serum concentration of Canagliflozin can be increased when it is combined with Vardenafil.
Varenicline
The serum concentration of Metformin can be increased when it is combined with Varenicline.
Velpatasvir
The serum concentration of Velpatasvir can be increased when it is combined with Canagliflozin.
Vemurafenib
The serum concentration of Canagliflozin can be increased when it is combined with Vemurafenib.
Venlafaxine
The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Metformin.
Venlafaxine
The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Canagliflozin.
Verapamil
The risk or severity of hypoglycemia can be increased when Verapamil is combined with Metformin.
Verapamil
The metabolism of Canagliflozin can be decreased when combined with Verapamil.
Vimseltinib
The serum concentration of Metformin can be increased when it is combined with Vimseltinib.
Vimseltinib
The serum concentration of Canagliflozin can be increased when it is combined with Vimseltinib.
Vincristine
The excretion of Vincristine can be decreased when combined with Canagliflozin.
Voclosporin
The serum concentration of Voclosporin can be increased when it is combined with Canagliflozin.
Vorapaxar
The serum concentration of Canagliflozin can be increased when it is combined with Vorapaxar.
Vorinostat
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.
Voxilaprevir
The serum concentration of Voxilaprevir can be increased when it is combined with Canagliflozin.
Warfarin
Metformin may decrease the excretion rate of Warfarin which could result in a higher serum level.
Warfarin
Canagliflozin may decrease the excretion rate of Warfarin which could result in a higher serum level.
Xylometazoline
The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Metformin.
Xylometazoline
The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Canagliflozin.
Ziconotide
The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Metformin.
Ziconotide
The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Canagliflozin.
Ziprasidone
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.
Zonisamide
The risk or severity of lactic acidosis can be increased when Zonisamide is combined with Metformin.
Zonisamide
The serum concentration of Canagliflozin can be increased when it is combined with Zonisamide.
Abacavir
Metformin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abacavir
Abacavir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Abaloparatide
The risk or severity of adverse effects can be increased when Abaloparatide is combined with Canagliflozin.
Acarbose
The serum concentration of Metformin can be decreased when it is combined with Acarbose.
Aceclofenac
Aceclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.
Aceclofenac
The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Canagliflozin.
Acetaminophen
Acetaminophen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Acetazolamide
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetazolamide.
Acetyl sulfisoxazole
The therapeutic efficacy of Metformin can be increased when used in combination with Acetyl sulfisoxazole.
Acetyl sulfisoxazole
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Acetyl sulfisoxazole.
Aclidinium
Metformin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Aclidinium
Aclidinium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Acrivastine
Metformin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acrivastine
Canagliflozin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir
Acyclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Adefovir dipivoxil
Adefovir dipivoxil may decrease the excretion rate of Metformin which could result in a higher serum level.
Adefovir dipivoxil
Adefovir dipivoxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Albuterol
The therapeutic efficacy of Metformin can be decreased when used in combination with Albuterol.
Albuterol
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Albuterol.
Albutrepenonacog alfa
Metformin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Albutrepenonacog alfa
Canagliflozin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Aldesleukin
Aldesleukin may decrease the excretion rate of Metformin which could result in a higher serum level.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.
Aliskiren
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Aliskiren.
Allopurinol
Metformin may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Allopurinol
Allopurinol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Almasilate
Metformin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almasilate
Canagliflozin may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan
Metformin may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Almotriptan
Almotriptan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Alprazolam
Metformin may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Alprazolam
Alprazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Amantadine
Amantadine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Canagliflozin.
Amiloride
The risk or severity of adverse effects can be increased when Amiloride is combined with Canagliflozin.
Ammonium chloride
Metformin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Ammonium chloride
The risk or severity of hyperkalemia can be increased when Ammonium chloride is combined with Canagliflozin.
Amoxicillin
Metformin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amoxicillin
Amoxicillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Amphetamine
Amphetamine may decrease the excretion rate of Metformin which could result in a higher serum level.
Amphetamine
Amphetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Amphotericin B
Amphotericin B may decrease the excretion rate of Metformin which could result in a higher serum level.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Canagliflozin.
Ampicillin
Metformin may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Ampicillin
Ampicillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.
Antipyrine
Antipyrine may decrease the excretion rate of Metformin which could result in a higher serum level.
Antipyrine
The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Canagliflozin.
Antithrombin III human
Metformin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antithrombin III human
Canagliflozin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Canagliflozin.
Apremilast
Metformin may decrease the excretion rate of Apremilast which could result in a higher serum level.
Apremilast
Apremilast may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Aprocitentan
Canagliflozin may increase the hypotensive activities of Aprocitentan.
Arformoterol
Metformin may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Arformoterol
Arformoterol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Arimoclomol
The serum concentration of Metformin can be increased when it is combined with Arimoclomol.
Aripiprazole
The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.
Aripiprazole lauroxil
Aripiprazole lauroxil may increase the hypotensive activities of Canagliflozin.
Arsenic trioxide
The therapeutic efficacy of Metformin can be decreased when used in combination with Arsenic trioxide.
Articaine
The therapeutic efficacy of Metformin can be decreased when used in combination with Articaine.
Asenapine
The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine.
Atazanavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Atazanavir.
Atomoxetine
Atomoxetine may decrease the excretion rate of Metformin which could result in a higher serum level.
Atomoxetine
Atomoxetine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Atorvastatin
Metformin may increase the hypolipidaemic activities of Atorvastatin.
Auranofin
Metformin may decrease the excretion rate of Auranofin which could result in a higher serum level.
Auranofin
Auranofin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Azacitidine
Metformin may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Azacitidine
Azacitidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Azathioprine
Metformin may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Azathioprine
Azathioprine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Azelaic acid
Metformin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Azelaic acid
Azelaic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Aztreonam
Metformin may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Aztreonam
Aztreonam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Bacitracin
Bacitracin may decrease the excretion rate of Metformin which could result in a higher serum level.
Bacitracin
Bacitracin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Baricitinib
Canagliflozin may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Beclomethasone dipropionate
The therapeutic efficacy of Metformin can be decreased when used in combination with Beclomethasone dipropionate.
Bendroflumethiazide
The therapeutic efficacy of Metformin can be decreased when used in combination with Bendroflumethiazide.
Benzatropine
Benzatropine may decrease the excretion rate of Metformin which could result in a higher serum level.
Benzatropine
Benzatropine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Benznidazole
Metformin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benznidazole
Canagliflozin may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Bepotastine
Metformin may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Bepotastine
Bepotastine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Betamethasone
The therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.
Bicisate
Metformin may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bicisate
Canagliflozin may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bictegravir
The excretion of Metformin can be decreased when combined with Bictegravir.
Bimatoprost
Metformin may decrease the excretion rate of Bimatoprost which could result in a higher serum level.
Bimatoprost
Bimatoprost may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Bismuth subgallate
Metformin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bismuth subgallate
Canagliflozin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bleomycin
Bleomycin may decrease the excretion rate of Metformin which could result in a higher serum level.
Bleomycin
Bleomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Bosentan
The therapeutic efficacy of Metformin can be increased when used in combination with Bosentan.
Bosentan
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Bosentan.
Bretylium
The risk or severity of adverse effects can be increased when Bretylium is combined with Canagliflozin.
Brexpiprazole
The therapeutic efficacy of Metformin can be decreased when used in combination with Brexpiprazole.
Brivaracetam
Metformin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Brivaracetam
Brivaracetam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Bromotheophylline
Bromotheophylline may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Bromotheophylline
Bromotheophylline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Bumetanide
The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Canagliflozin.
Bupropion
Bupropion may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Buspirone
Metformin may decrease the excretion rate of Buspirone which could result in a higher serum level.
Buspirone
Buspirone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Capecitabine
Metformin may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Capecitabine
Capecitabine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Captopril
The risk or severity of lactic acidosis can be increased when Captopril is combined with Metformin.
Carbidopa
Carbidopa may decrease the excretion rate of Metformin which could result in a higher serum level.
Carbidopa
Carbidopa may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Carboplatin
Carboplatin may decrease the excretion rate of Metformin which could result in a higher serum level.
Carboplatin
Carboplatin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Carmustine
Carmustine may decrease the excretion rate of Metformin which could result in a higher serum level.
Carmustine
Carmustine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefaclor
Cefaclor may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefaclor
Cefaclor may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefadroxil
Cefadroxil may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefadroxil
Cefadroxil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefazolin
Cefazolin may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefazolin
Cefazolin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefdinir
Metformin may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cefdinir
Cefdinir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefditoren
Cefditoren may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefditoren
Cefditoren may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefepime
Cefepime may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefepime
Cefepime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefotaxime
Cefotaxime may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefotaxime
Cefotaxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefotetan
Cefotetan may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefotetan
Cefotetan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefoxitin
Cefoxitin may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefoxitin
Cefoxitin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefpodoxime
Cefpodoxime may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefpodoxime
Cefpodoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefprozil
Cefprozil may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefprozil
Cefprozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ceftaroline fosamil
Ceftaroline fosamil may decrease the excretion rate of Metformin which could result in a higher serum level.
Ceftaroline fosamil
Ceftaroline fosamil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ceftazidime
Ceftazidime may decrease the excretion rate of Metformin which could result in a higher serum level.
Ceftazidime
Ceftazidime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ceftibuten
Ceftibuten may decrease the excretion rate of Metformin which could result in a higher serum level.
Ceftibuten
Ceftibuten may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ceftizoxime
Ceftizoxime may decrease the excretion rate of Metformin which could result in a higher serum level.
Ceftizoxime
Ceftizoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ceftolozane
Metformin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftolozane
Canagliflozin may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone
Ceftriaxone may decrease the excretion rate of Metformin which could result in a higher serum level.
Ceftriaxone
Ceftriaxone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cefuroxime
Cefuroxime may decrease the excretion rate of Metformin which could result in a higher serum level.
Cefuroxime
Cefuroxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Celecoxib
The therapeutic efficacy of Metformin can be increased when used in combination with Celecoxib.
Celecoxib
The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Canagliflozin.
Cephalexin
Cephalexin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ceritinib
The therapeutic efficacy of Metformin can be decreased when used in combination with Ceritinib.
Certolizumab pegol
Metformin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Certolizumab pegol
Certolizumab pegol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cetirizine
Metformin may decrease the excretion rate of Cetirizine which could result in a higher serum level.
Cetirizine
Cetirizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cevimeline
Cevimeline may decrease the excretion rate of Metformin which could result in a higher serum level.
Cevimeline
Cevimeline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Chloroquine
Metformin may decrease the excretion rate of Chloroquine which could result in a higher serum level.
Chloroquine
Chloroquine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Chlorothiazide
The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.
Chlorpromazine
The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorpromazine.
Chlorthalidone
The therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone.
Chlorzoxazone
Metformin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Chlorzoxazone
Chlorzoxazone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Chondroitin sulfate
Metformin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chondroitin sulfate
Canagliflozin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride
Metformin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic chloride
Canagliflozin may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromium
Metformin may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium
Canagliflozin may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium nicotinate
Metformin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromium nicotinate
Canagliflozin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Ciclesonide
The therapeutic efficacy of Metformin can be decreased when used in combination with Ciclesonide.
Cidofovir
Cidofovir may decrease the excretion rate of Metformin which could result in a higher serum level.
Cidofovir
Cidofovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cilostazol
Metformin may decrease the excretion rate of Cilostazol which could result in a higher serum level.
Cilostazol
Cilostazol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cimetidine
The serum concentration of Metformin can be increased when it is combined with Cimetidine.
Cimetidine
Cimetidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Clobazam
Metformin may decrease the excretion rate of Clobazam which could result in a higher serum level.
Clobetasol propionate
The therapeutic efficacy of Metformin can be decreased when used in combination with Clobetasol propionate.
Clofarabine
Metformin may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Canagliflozin.
Clonazepam
Metformin may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Clonazepam
Clonazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.
Clorazepic acid
Metformin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clorazepic acid
Clorazepic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Clove oil
Metformin may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clove oil
Canagliflozin may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine
The therapeutic efficacy of Metformin can be decreased when used in combination with Clozapine.
Colchicine
Metformin may decrease the excretion rate of Colchicine which could result in a higher serum level.
Colistimethate
Colistimethate may decrease the excretion rate of Metformin which could result in a higher serum level.
Colistimethate
Colistimethate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Conivaptan
Conivaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Corticotropin
The therapeutic efficacy of Metformin can be decreased when used in combination with Corticotropin.
Cortisone acetate
The therapeutic efficacy of Metformin can be decreased when used in combination with Cortisone acetate.
Cyanocobalamin
Cyanocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.
Cyanocobalamin
Cyanocobalamin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Cyclosporine
Cyclosporine may decrease the excretion rate of Metformin which could result in a higher serum level.
Dabigatran etexilate
Metformin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dabrafenib
The therapeutic efficacy of Metformin can be decreased when used in combination with Dabrafenib.
Dacarbazine
Metformin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Dacarbazine
Dacarbazine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dalfampridine
The serum concentration of Dalfampridine can be increased when it is combined with Metformin.
Dalfampridine
Dalfampridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dalteparin
The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Canagliflozin.
Danazol
The therapeutic efficacy of Metformin can be decreased when used in combination with Danazol.
Dantrolene
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Canagliflozin.
Daptomycin
Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level.
Darunavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Darunavir.
Dasiglucagon
Canagliflozin may increase the hypotensive activities of Dasiglucagon.
Deferiprone
Metformin may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Deferiprone
Deferiprone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Deflazacort
The therapeutic efficacy of Metformin can be decreased when used in combination with Deflazacort.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Canagliflozin.
Desmopressin
Desmopressin may decrease the excretion rate of Metformin which could result in a higher serum level.
Desmopressin
Desmopressin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Desogestrel
The therapeutic efficacy of Metformin can be decreased when used in combination with Desogestrel.
Deutetrabenazine
Metformin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Deutetrabenazine
Canagliflozin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone
The therapeutic efficacy of Metformin can be decreased when used in combination with Dexamethasone.
Dexmedetomidine
Metformin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.
Dexpanthenol
Metformin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexpanthenol
Canagliflozin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane
Metformin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dexrazoxane
Dexrazoxane may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dextran
Metformin may decrease the excretion rate of Dextran which could result in a higher serum level.
Dextran
Canagliflozin may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate
Diatrizoate may decrease the excretion rate of Metformin which could result in a higher serum level.
Diatrizoate
Diatrizoate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Diazepam
Metformin may decrease the excretion rate of Diazepam which could result in a higher serum level.
Diazepam
Diazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Diazoxide
The therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide.
Diclofenac
Diclofenac may decrease the excretion rate of Metformin which could result in a higher serum level.
Diclofenac
The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Canagliflozin.
Diclofenamide
The risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.
Dicyclomine
Metformin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Dicyclomine
Dicyclomine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Didanosine
Metformin may decrease the excretion rate of Didanosine which could result in a higher serum level.
Didanosine
Didanosine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dienogest
The therapeutic efficacy of Metformin can be decreased when used in combination with Dienogest.
Dimercaprol
Metformin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimercaprol
Dimercaprol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dimethyl sulfoxide
Metformin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Dimethyl sulfoxide
Dimethyl sulfoxide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dinutuximab
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.
DL-Methylephedrine
Metformin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
DL-Methylephedrine
Canagliflozin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine
Metformin may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Dobutamine
Dobutamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Dopamine
Dopamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Doxazosin
The risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.
Doxycycline
Doxycycline may decrease the excretion rate of Metformin which could result in a higher serum level.
Doxycycline
Doxycycline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Drospirenone
The therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.
Droxidopa
Metformin may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Droxidopa
Droxidopa may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Duloxetine
The risk or severity of orthostatic hypotension and syncope can be increased when Canagliflozin is combined with Duloxetine.
Edoxaban
Metformin may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium
Metformin may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Edrophonium
Edrophonium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Emtricitabine
The excretion of Emtricitabine can be decreased when combined with Metformin.
Enalapril
The risk or severity of lactic acidosis can be increased when Enalapril is combined with Metformin.
Enalaprilat
The risk or severity of lactic acidosis can be increased when Enalaprilat is combined with Metformin.
Enoxaparin
The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Canagliflozin.
Ensartinib
The serum concentration of Ensartinib can be increased when it is combined with Canagliflozin.
Enzalutamide
Metformin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Epinephrine
The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine.
Eplerenone
Eplerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Eplerenone
The risk or severity of adverse effects can be increased when Eplerenone is combined with Canagliflozin.
Epoprostenol
Metformin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Canagliflozin.
Ertapenem
Ertapenem may decrease the excretion rate of Metformin which could result in a higher serum level.
Ertapenem
Ertapenem may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.
Estazolam
Metformin may decrease the excretion rate of Estazolam which could result in a higher serum level.
Estazolam
Estazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Estradiol
The therapeutic efficacy of Metformin can be decreased when used in combination with Estradiol.
Estradiol acetate
Canagliflozin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate
Canagliflozin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol valerate
Canagliflozin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estrone sulfate
The therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate.
Eszopiclone
Metformin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Eszopiclone
Eszopiclone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Etacrynic acid
The therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.
Ethambutol
Ethambutol may decrease the excretion rate of Metformin which could result in a higher serum level.
Ethambutol
Ethambutol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ethenzamide
Ethenzamide may decrease the excretion rate of Metformin which could result in a higher serum level.
Ethenzamide
The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Ethenzamide.
Ethinylestradiol
The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinylestradiol.
Ethynodiol diacetate
The therapeutic efficacy of Metformin can be decreased when used in combination with Ethynodiol diacetate.
Etodolac
Etodolac may decrease the excretion rate of Metformin which could result in a higher serum level.
Etodolac
The risk or severity of hyperkalemia can be increased when Etodolac is combined with Canagliflozin.
Etomidate
Etomidate may decrease the excretion rate of Metformin which could result in a higher serum level.
Etomidate
Etomidate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Etonogestrel
The therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel.
Eucalyptus oil
Metformin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Eucalyptus oil
Canagliflozin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Evening primrose oil
Metformin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Evening primrose oil
Canagliflozin may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Everolimus
The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.
Fenofibrate
Fenofibrate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fenofibric acid
Metformin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenofibric acid
Canagliflozin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam
Metformin may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Canagliflozin.
Fenoprofen
Fenoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.
Fenoprofen
The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Canagliflozin.
Fentanyl
Metformin may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Fentanyl
Fentanyl may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fesoterodine
Metformin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Fesoterodine
Fesoterodine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Finerenone
Finerenone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Finerenone
The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Finerenone.
Fish oil
The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Fish oil.
Flavoxate
Metformin may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Flavoxate
Flavoxate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Flecainide
The excretion of Flecainide can be decreased when combined with Metformin.
Florbetaben F-18
Metformin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetaben F-18
Canagliflozin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir F-18
Metformin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Florbetapir F-18
Canagliflozin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine
Floxuridine may decrease the excretion rate of Metformin which could result in a higher serum level.
Floxuridine
Floxuridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Flucytosine
Metformin may decrease the excretion rate of Flucytosine which could result in a higher serum level.
Flucytosine
Flucytosine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fludeoxyglucose (18F)
Metformin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludeoxyglucose (18F)
Canagliflozin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Fludrocortisone
The therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.
Flumazenil
Metformin may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Flumazenil
Flumazenil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fluorometholone
The therapeutic efficacy of Metformin can be decreased when used in combination with Fluorometholone.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Metformin.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Canagliflozin.
Flurazepam
Flurazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Flurbiprofen
Flurbiprofen may decrease the excretion rate of Metformin which could result in a higher serum level.
Flurbiprofen
The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Canagliflozin.
Flutamide
Metformin may decrease the excretion rate of Flutamide which could result in a higher serum level.
Flutamide
Flutamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fluticasone furoate
The therapeutic efficacy of Metformin can be decreased when used in combination with Fluticasone furoate.
Fluvastatin
Metformin may increase the hypolipidaemic activities of Fluvastatin.
Folic acid
Folic acid may decrease the excretion rate of Metformin which could result in a higher serum level.
Folic acid
Folic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fomepizole
Metformin may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fomepizole
Fomepizole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fondaparinux
Metformin may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Fondaparinux
Fondaparinux may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fosamprenavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Fosamprenavir.
Foscarnet
Foscarnet may decrease the excretion rate of Metformin which could result in a higher serum level.
Foscarnet
Foscarnet may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fosfomycin
Metformin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosfomycin
Fosfomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Fosinopril
The risk or severity of lactic acidosis can be increased when Fosinopril is combined with Metformin.
Fostamatinib
The risk or severity of hypotension can be increased when Fostamatinib is combined with Canagliflozin.
Furosemide
The therapeutic efficacy of Metformin can be decreased when used in combination with Furosemide.
Gabapentin enacarbil
Metformin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gabapentin enacarbil
Gabapentin enacarbil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Gadobenic acid
Metformin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level.
Gadobenic acid
Gadobenic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Gadodiamide
Gadodiamide may decrease the excretion rate of Metformin which could result in a higher serum level.
Gadodiamide
Gadodiamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Gadofosveset trisodium
Metformin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadofosveset trisodium
Gadofosveset trisodium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Gadoteric acid
Metformin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteric acid
Canagliflozin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol
Metformin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Gadoteridol
Gadoteridol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ganciclovir
Ganciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Gemcitabine
Metformin may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
Gemfibrozil
Metformin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.
Gemfibrozil
Gemfibrozil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Gilteritinib
The excretion of Metformin can be decreased when combined with Gilteritinib.
Givosiran
Givosiran may decrease the excretion rate of Metformin which could result in a higher serum level.
Givosiran
Givosiran may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Glycerol phenylbutyrate
Metformin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Glycerol phenylbutyrate
Canagliflozin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Glycopyrronium
The serum concentration of Metformin can be increased when it is combined with Glycopyrronium.
Golodirsen
Metformin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Golodirsen
Canagliflozin may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin
The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.
Guanfacine
Metformin may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.
Haloperidol
The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol.
Heparin
The risk or severity of hyperkalemia can be increased when Heparin is combined with Canagliflozin.
Histrelin
The therapeutic efficacy of Metformin can be decreased when used in combination with Histrelin.
Hydralazine
Metformin may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Hydralazine
The risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.
Hydrochlorothiazide
The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrochlorothiazide.
Hydrocortisone
The therapeutic efficacy of Metformin can be decreased when used in combination with Hydrocortisone.
Hydromorphone
Hydromorphone may decrease the excretion rate of Metformin which could result in a higher serum level.
Hydromorphone
Hydromorphone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Hydroxocobalamin
Hydroxocobalamin may decrease the excretion rate of Metformin which could result in a higher serum level.
Hydroxocobalamin
Hydroxocobalamin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Hydroxyethyl Starch
Metformin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyethyl Starch
Canagliflozin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyprogesterone caproate
The therapeutic efficacy of Metformin can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibuprofen
Ibuprofen may decrease the excretion rate of Metformin which could result in a higher serum level.
Ibuprofen
The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Canagliflozin.
Ibutilide
Ibutilide may decrease the excretion rate of Metformin which could result in a higher serum level.
Ibutilide
Ibutilide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Icatibant
Metformin may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icatibant
Icatibant may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Icosapent
Icosapent may decrease the excretion rate of Metformin which could result in a higher serum level.
Icosapent
The risk or severity of hyperkalemia can be increased when Icosapent is combined with Canagliflozin.
Idarucizumab
Metformin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idarucizumab
Canagliflozin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Ifosfamide
Metformin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Ifosfamide
Ifosfamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Iloperidone
The therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Canagliflozin.
Indapamide
The therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.
Indigotindisulfonic acid
Metformin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indigotindisulfonic acid
Canagliflozin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indinavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Indinavir.
Inositol
Metformin may decrease the excretion rate of Inositol which could result in a higher serum level.
Inositol
Canagliflozin may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen
Inotersen may decrease the excretion rate of Metformin which could result in a higher serum level.
Inotersen
Inotersen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Iobenguane sulfate I-123
Metformin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iobenguane sulfate I-123
Canagliflozin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol
Iodixanol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ioflupane I-123
Metformin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Ioflupane I-123
Ioflupane I-123 may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Iopromide
Canagliflozin may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid
Metformin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Iothalamic acid
Canagliflozin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol
Canagliflozin may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ipecac
Metformin may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipecac
Canagliflozin may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab
Metformin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Ipilimumab
Ipilimumab may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Isocarboxazid
Isocarboxazid may increase the hypoglycemic activities of Metformin.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Canagliflozin.
Isoniazid
The therapeutic efficacy of Metformin can be decreased when used in combination with Isoniazid.
Isosorbide
Isosorbide may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide
Isosorbide may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide dinitrate
The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Canagliflozin.
Isosorbide mononitrate
Metformin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Isosorbide mononitrate
The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Canagliflozin.
Isosulfan blue
Metformin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isosulfan blue
Canagliflozin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin
Metformin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Isotretinoin
Isotretinoin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Isoxsuprine
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.
Ixazomib
Metformin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ixazomib
Canagliflozin may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ketamine
Metformin may decrease the excretion rate of Ketamine which could result in a higher serum level.
Ketamine
Ketamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ketoprofen
Ketoprofen may decrease the excretion rate of Metformin which could result in a higher serum level.
Ketoprofen
The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Canagliflozin.
Ketorolac
Ketorolac may decrease the excretion rate of Metformin which could result in a higher serum level.
Ketorolac
The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Canagliflozin.
Ketotifen
The risk or severity of thrombocytopenia can be increased when Metformin is combined with Ketotifen.
Ketotifen
The risk or severity of thrombocytopenia can be increased when Canagliflozin is combined with Ketotifen.
L-Acetylleucine
The serum concentration of Canagliflozin can be increased when it is combined with L-Acetylleucine.
Lamivudine
Metformin may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Lamivudine
Lamivudine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Lamotrigine
The serum concentration of Metformin can be increased when it is combined with Lamotrigine.
Lamotrigine
The risk or severity of hyperkalemia can be increased when Lamotrigine is combined with Canagliflozin.
Landiolol
The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Landiolol.
Lanreotide
The therapeutic efficacy of Metformin can be decreased when used in combination with Lanreotide.
Ledipasvir
Metformin may decrease the excretion rate of Ledipasvir which could result in a higher serum level.
Lenalidomide
Metformin may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Lenalidomide
Lenalidomide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Leuprolide
The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.
Levocarnitine
Metformin may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Levocarnitine
Levocarnitine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Levocetirizine
Metformin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.
Levocetirizine
Levocetirizine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Levodopa
The risk or severity of hypotension and orthostatic hypotension can be increased when Canagliflozin is combined with Levodopa.
Levomenthol
The risk or severity of hyperkalemia can be increased when Levomenthol is combined with Canagliflozin.
Levonorgestrel
The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel.
Levosalbutamol
Metformin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Levosalbutamol
Canagliflozin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Levothyroxine
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levothyroxine.
Linezolid
Linezolid may increase the hypoglycemic activities of Metformin.
Lisinopril
The risk or severity of lactic acidosis can be increased when Lisinopril is combined with Metformin.
Lithium carbonate
The therapeutic efficacy of Metformin can be decreased when used in combination with Lithium carbonate.
Lithium carbonate
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lithium carbonate.
Lithium citrate
Lithium citrate may decrease the excretion rate of Metformin which could result in a higher serum level.
Lithium citrate
Lithium citrate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Lofexidine
Metformin may decrease the excretion rate of Lofexidine which could result in a higher serum level.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Canagliflozin.
Loperamide
The excretion of Loperamide can be decreased when combined with Canagliflozin.
Lopinavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.
Lorazepam
Lorazepam may decrease the excretion rate of Metformin which could result in a higher serum level.
Lorazepam
Lorazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Lovastatin
Metformin may increase the hypolipidaemic activities of Lovastatin.
Lubiprostone
Metformin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Lubiprostone
Lubiprostone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Lurasidone
The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.
Macitentan
Metformin may decrease the excretion rate of Macitentan which could result in a higher serum level.
Macitentan
Canagliflozin may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium carbonate
Metformin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium carbonate
Canagliflozin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride
Metformin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium chloride
Canagliflozin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hydroxide
Metformin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium hydroxide
Canagliflozin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium salicylate
Magnesium salicylate may decrease the excretion rate of Metformin which could result in a higher serum level.
Magnesium salicylate
The risk or severity of hyperkalemia can be increased when Magnesium salicylate is combined with Canagliflozin.
Magnesium trisilicate
Metformin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Magnesium trisilicate
Canagliflozin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mannitol
Mannitol may decrease the excretion rate of Metformin which could result in a higher serum level.
Maprotiline
Metformin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Maprotiline
Maprotiline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Mecamylamine
Metformin may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.
Meclofenamic acid
Meclofenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.
Meclofenamic acid
The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Canagliflozin.
Medroxyprogesterone acetate
The therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acid
Mefenamic acid may decrease the excretion rate of Metformin which could result in a higher serum level.
Megestrol acetate
The therapeutic efficacy of Metformin can be decreased when used in combination with Megestrol acetate.
Meloxicam
Meloxicam may decrease the excretion rate of Metformin which could result in a higher serum level.
Meloxicam
The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Canagliflozin.
Memantine
Metformin may decrease the excretion rate of Memantine which could result in a higher serum level.
Memantine
Memantine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Meperidine
Metformin may decrease the excretion rate of Meperidine which could result in a higher serum level.
Meperidine
Meperidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Mepivacaine
Metformin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.
Mepivacaine
Mepivacaine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Meropenem
Metformin may decrease the excretion rate of Meropenem which could result in a higher serum level.
Meropenem
Meropenem may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Metamfetamine
Metformin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamfetamine
Metamfetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Metaxalone
Metformin may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Metaxalone
Metaxalone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Methadone
Metformin may decrease the excretion rate of Methadone which could result in a higher serum level.
Methadone
Methadone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Methazolamide
The risk or severity of adverse effects can be increased when Methazolamide is combined with Canagliflozin.
Methimazole
Metformin may decrease the excretion rate of Methimazole which could result in a higher serum level.
Methotrexate
Methotrexate may decrease the excretion rate of Metformin which could result in a higher serum level.
Methotrexate
Methotrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Methoxsalen
Metformin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Methoxsalen
Methoxsalen may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Methyldopa
Metformin may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Methyldopa
The risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.
Methylnaltrexone
Metformin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methylnaltrexone
Methylnaltrexone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Methylprednisolone
The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.
Methyltestosterone
Methyltestosterone may increase the hypoglycemic activities of Metformin.
Methyltestosterone
Methyltestosterone may increase the hypoglycemic activities of Canagliflozin.
Metoclopramide
Metformin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.
Metoclopramide
Metoclopramide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Metolazone
The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.
Metreleptin
The metabolism of Canagliflozin can be increased when combined with Metreleptin.
Metyrapone
Metformin may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Metyrapone
Metyrapone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Metyrosine
Canagliflozin may increase the hypotensive activities of Metyrosine.
Midazolam
Metformin may decrease the excretion rate of Midazolam which could result in a higher serum level.
Migalastat
Metformin may decrease the excretion rate of Migalastat which could result in a higher serum level.
Migalastat
Migalastat may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Milrinone
Milrinone may decrease the excretion rate of Metformin which could result in a higher serum level.
Milrinone
Milrinone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Minoxidil
The risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.
Mirabegron
Metformin may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mitapivat
The therapeutic efficacy of Metformin can be increased when used in combination with Mitapivat.
Moexipril
The risk or severity of lactic acidosis can be increased when Moexipril is combined with Metformin.
Mometasone furoate
The therapeutic efficacy of Metformin can be decreased when used in combination with Mometasone furoate.
Mycophenolate mofetil
Metformin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
Mycophenolate mofetil
Mycophenolate mofetil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Mycophenolic acid
Metformin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Mycophenolic acid
Mycophenolic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
N-acetyltyrosine
Metformin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
N-acetyltyrosine
Canagliflozin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Canagliflozin.
Nabumetone
Nabumetone may decrease the excretion rate of Metformin which could result in a higher serum level.
Nabumetone
The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Canagliflozin.
Naldemedine
Metformin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Naldemedine
Canagliflozin may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene
Metformin may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Nalmefene
Nalmefene may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Naloxone
Metformin may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naloxone
Naloxone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Nandrolone decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Metformin.
Nandrolone decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Canagliflozin.
Naproxen
Naproxen may decrease the excretion rate of Metformin which could result in a higher serum level.
Naproxen
The risk or severity of hyperkalemia can be increased when Naproxen is combined with Canagliflozin.
Nedocromil
Metformin may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Nedocromil
Nedocromil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Nelfinavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir.
Niacin
The therapeutic efficacy of Metformin can be decreased when used in combination with Niacin.
Nilotinib
The therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.
Nilutamide
Metformin may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Nilutamide
Nilutamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Nitric Oxide
Metformin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Canagliflozin.
Nitrofurantoin
Metformin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nitrofurantoin
The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Canagliflozin.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.
Nitroprusside
Nitroprusside may decrease the excretion rate of Metformin which could result in a higher serum level.
Nitroprusside
The risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.
Nitrous acid
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Nitrous acid.
Norethisterone
The therapeutic efficacy of Metformin can be decreased when used in combination with Norethisterone.
Norgestimate
The therapeutic efficacy of Metformin can be decreased when used in combination with Norgestimate.
Obinutuzumab
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Obinutuzumab.
Octinoxate
Metformin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Octinoxate
Canagliflozin may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Olanzapine
The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine.
Omaveloxolone
The serum concentration of Canagliflozin can be decreased when it is combined with Omaveloxolone.
Opicapone
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Opicapone.
Opium
Metformin may decrease the excretion rate of Opium which could result in a higher serum level.
Opium
Canagliflozin may decrease the excretion rate of Opium which could result in a higher serum level.
Oseltamivir
Oseltamivir may decrease the excretion rate of Metformin which could result in a higher serum level.
Oseltamivir
Oseltamivir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Oxacillin
Metformin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxacillin
Oxacillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Metformin.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Canagliflozin.
Oxaprozin
Oxaprozin may decrease the excretion rate of Metformin which could result in a higher serum level.
Oxaprozin
The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Canagliflozin.
Oxazepam
Metformin may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxazepam
Oxazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Oxybenzone
Metformin may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxybenzone
Oxybenzone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Metformin.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Canagliflozin.
Oxyquinoline
Metformin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Oxyquinoline
Canagliflozin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.
Paliperidone
The therapeutic efficacy of Metformin can be decreased when used in combination with Paliperidone.
Palonosetron
Metformin may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Palonosetron
Palonosetron may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pamidronic acid
Pamidronic acid may decrease the excretion rate of Metformin which could result in a higher serum level.
Pamidronic acid
Pamidronic acid may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pantoprazole
Pantoprazole may decrease the excretion rate of Metformin which could result in a higher serum level.
Pantoprazole
Pantoprazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Papaverine
The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.
Parecoxib
Parecoxib may decrease the excretion rate of Metformin which could result in a higher serum level.
Parecoxib
The risk or severity of hyperkalemia can be increased when Parecoxib is combined with Canagliflozin.
Paromomycin
Paromomycin may decrease the excretion rate of Metformin which could result in a higher serum level.
Paromomycin
Paromomycin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pasireotide
The therapeutic efficacy of Metformin can be decreased when used in combination with Pasireotide.
Pentamidine
The therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine.
Pentetic acid
Metformin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentetic acid
Canagliflozin may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital
Pentobarbital may decrease the excretion rate of Metformin which could result in a higher serum level.
Pentoxifylline
Metformin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Pentoxifylline
Pentoxifylline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Perindopril
The risk or severity of lactic acidosis can be increased when Perindopril is combined with Metformin.
Permethrin
Metformin may decrease the excretion rate of Permethrin which could result in a higher serum level.
Permethrin
Permethrin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Phenazopyridine
Phenazopyridine may decrease the excretion rate of Metformin which could result in a higher serum level.
Phenazopyridine
Phenazopyridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Phenelzine
Phenelzine may increase the hypoglycemic activities of Metformin.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Canagliflozin.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Canagliflozin.
Phenytoin
The therapeutic efficacy of Metformin can be decreased when used in combination with Phenytoin.
Phosphoric acid
Metformin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phosphoric acid
Canagliflozin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone
Metformin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Phylloquinone
Phylloquinone may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Picosulfuric acid
Metformin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Picosulfuric acid
Canagliflozin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Piperacillin
Piperacillin may decrease the excretion rate of Metformin which could result in a higher serum level.
Piperacillin
Piperacillin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Piroxicam
Piroxicam may decrease the excretion rate of Metformin which could result in a higher serum level.
Piroxicam
The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Canagliflozin.
Pitavastatin
Metformin may increase the hypolipidaemic activities of Pitavastatin.
Pitolisant
Metformin may decrease the excretion rate of Pitolisant which could result in a higher serum level.
Plerixafor
Metformin may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Plerixafor
Plerixafor may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Polythiazide
The therapeutic efficacy of Metformin can be decreased when used in combination with Polythiazide.
Pomalidomide
Metformin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Potassium
Potassium may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate
Metformin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate
Metformin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation
Metformin may decrease the excretion rate of Potassium cation which could result in a higher serum level.
Potassium chloride
Metformin may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Potassium citrate
Potassium citrate may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate
Metformin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium sulfate
Metformin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralatrexate
Metformin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralatrexate
Pralatrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pralidoxime
Metformin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Pralidoxime
Pralidoxime may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pramipexole
Metformin may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Canagliflozin.
Prasugrel
Metformin may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Prasugrel
Prasugrel may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pravastatin
Metformin may increase the hypolipidaemic activities of Pravastatin.
Prazosin
The risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.
Prednisolone
The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.
Prednisone
The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisone.
Probenecid
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Probenecid.
Procaine
Procaine may increase the hypoglycemic activities of Metformin.
Procaine benzylpenicillin
Metformin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procaine benzylpenicillin
Canagliflozin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine
Procarbazine may increase the hypoglycemic activities of Metformin.
Progesterone
The therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.
Promethazine
Metformin may decrease the excretion rate of Promethazine which could result in a higher serum level.
Promethazine
Promethazine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Propantheline
Metformin may decrease the excretion rate of Propantheline which could result in a higher serum level.
Propantheline
Propantheline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Canagliflozin.
Propyphenazone
Propyphenazone may decrease the excretion rate of Metformin which could result in a higher serum level.
Propyphenazone
The risk or severity of hyperkalemia can be increased when Canagliflozin is combined with Propyphenazone.
Prucalopride
Metformin may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pseudoephedrine
The therapeutic efficacy of Metformin can be decreased when used in combination with Pseudoephedrine.
Pyrantel
Metformin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrantel
Canagliflozin may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide
Metformin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Pyrazinamide
Pyrazinamide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Pyridoxine
Pyridoxine may decrease the excretion rate of Metformin which could result in a higher serum level.
Pyridoxine
Pyridoxine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Quetiapine
The therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.
Quinapril
The risk or severity of lactic acidosis can be increased when Quinapril is combined with Metformin.
Rabeprazole
Metformin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Rabeprazole
Rabeprazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ramelteon
Metformin may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Ramelteon
Ramelteon may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ramipril
The risk or severity of lactic acidosis can be increased when Ramipril is combined with Metformin.
Ranitidine
Ranitidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Rasagiline
Rasagiline may increase the hypoglycemic activities of Metformin.
Remdesivir
The excretion of Metformin can be decreased when combined with Remdesivir.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Canagliflozin.
Reserpine
Reserpine may decrease the excretion rate of Metformin which could result in a higher serum level.
Resorcinol
Metformin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Resorcinol
Canagliflozin may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Ribavirin
Metformin may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribavirin
Ribavirin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Rilzabrutinib
The metabolism of Canagliflozin can be decreased when combined with Rilzabrutinib.
Ripretinib
The excretion of Metformin can be decreased when combined with Ripretinib.
Risperidone
The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.
Risperidone
Canagliflozin may increase the hypotensive activities of Risperidone.
Ritonavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.
Rivaroxaban
Metformin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rizatriptan
Metformin may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rizatriptan
Rizatriptan may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Roflumilast
Metformin may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Roflumilast
Roflumilast may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.
Ropivacaine
Ropivacaine may decrease the excretion rate of Metformin which could result in a higher serum level.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Canagliflozin.
Rosuvastatin
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Rosuvastatin.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Canagliflozin.
Ruxolitinib
Metformin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Ruxolitinib
Ruxolitinib may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Sacubitril
Metformin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Sacubitril
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sacubitril.
Safinamide
Safinamide may increase the hypoglycemic activities of Metformin.
Salicylamide
Salicylamide may decrease the excretion rate of Metformin which could result in a higher serum level.
Salicylamide
The risk or severity of hyperkalemia can be increased when Salicylamide is combined with Canagliflozin.
Salmon calcitonin
Salmon calcitonin may decrease the excretion rate of Metformin which could result in a higher serum level.
Salmon calcitonin
Salmon calcitonin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Salsalate
Salsalate may decrease the excretion rate of Metformin which could result in a higher serum level.
Salsalate
The risk or severity of hyperkalemia can be increased when Salsalate is combined with Canagliflozin.
Saquinavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.
Secobarbital
Metformin may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Selegiline
Selegiline may increase the hypoglycemic activities of Metformin.
Selenious acid
Metformin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenious acid
Canagliflozin may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium
Metformin may decrease the excretion rate of Selenium which could result in a higher serum level.
Selenium
Canagliflozin may decrease the excretion rate of Selenium which could result in a higher serum level.
Selpercatinib
The excretion of Metformin can be decreased when combined with Selpercatinib.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Canagliflozin.
Simvastatin
Metformin may increase the hypolipidaemic activities of Simvastatin.
Sirolimus
The therapeutic efficacy of Metformin can be decreased when used in combination with Sirolimus.
Sodium acetate
Metformin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium acetate
Canagliflozin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium fluoride
Metformin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium fluoride
Canagliflozin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate
Metformin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sodium sulfate
Canagliflozin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir
Metformin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solriamfetol
Metformin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Solriamfetol
Canagliflozin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Sorafenib
Metformin may decrease the excretion rate of Sorafenib which could result in a higher serum level.
Sorbitol
Metformin may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Sorbitol
Sorbitol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Sotatercept
Canagliflozin may increase the hypotensive activities of Sotatercept.
Spironolactone
Spironolactone may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Stiripentol
Metformin may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Succinylcholine
The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Canagliflozin.
Sucralfate
Metformin may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Sucralfate
Sucralfate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Canagliflozin.
Sulbactam
Metformin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulbactam
Canagliflozin may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfamethizole
The therapeutic efficacy of Metformin can be increased when used in combination with Sulfamethizole.
Sulfamethizole
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfamethizole.
Sulindac
Sulindac may decrease the excretion rate of Metformin which could result in a higher serum level.
Sulindac
The risk or severity of hyperkalemia can be increased when Sulindac is combined with Canagliflozin.
Sumatriptan
The therapeutic efficacy of Metformin can be increased when used in combination with Sumatriptan.
Sumatriptan
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sumatriptan.
Synthetic Conjugated Estrogens, A
Metformin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Synthetic Conjugated Estrogens, A
Canagliflozin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Synthetic Conjugated Estrogens, B
Metformin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Synthetic Conjugated Estrogens, B
Canagliflozin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrolimus
The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus.
Tadalafil
Metformin may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Tadalafil
Tadalafil may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Talazoparib
The serum concentration of Talazoparib can be increased when it is combined with Canagliflozin.
Tamsulosin
The therapeutic efficacy of Metformin can be increased when used in combination with Tamsulosin.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Canagliflozin.
Tasimelteon
Metformin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Tasimelteon
Canagliflozin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Technetium Tc-99m exametazime
Metformin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m exametazime
Canagliflozin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate
Metformin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Technetium Tc-99m pyrophosphate
Canagliflozin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Teduglutide
Metformin may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Teduglutide
Teduglutide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Telavancin
Metformin may decrease the excretion rate of Telavancin which could result in a higher serum level.
Telavancin
Telavancin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Temazepam
Temazepam may decrease the excretion rate of Metformin which could result in a higher serum level.
Temazepam
Temazepam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Temozolomide
Metformin may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Temozolomide
Temozolomide may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Temsirolimus
The therapeutic efficacy of Metformin can be decreased when used in combination with Temsirolimus.
Tenofovir disoproxil
Tenofovir disoproxil may decrease the excretion rate of Metformin which could result in a higher serum level.
Teprotumumab
The therapeutic efficacy of Metformin can be decreased when used in combination with Teprotumumab.
Terazosin
The risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.
Terbutaline
Metformin may decrease the excretion rate of Terbutaline which could result in a higher serum level.
Terbutaline
Terbutaline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Testosterone
Testosterone may increase the hypoglycemic activities of Metformin.
Testosterone
Testosterone may increase the hypoglycemic activities of Canagliflozin.
Testosterone cypionate
Testosterone cypionate may increase the hypoglycemic activities of Metformin.
Testosterone cypionate
Testosterone cypionate may increase the hypoglycemic activities of Canagliflozin.
Testosterone enanthate
Testosterone enanthate may increase the hypoglycemic activities of Metformin.
Testosterone enanthate
Testosterone enanthate may increase the hypoglycemic activities of Canagliflozin.
Testosterone propionate
Testosterone propionate may increase the hypoglycemic activities of Metformin.
Testosterone propionate
Testosterone propionate may increase the hypoglycemic activities of Canagliflozin.
Testosterone undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Metformin.
Testosterone undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Canagliflozin.
Tetracycline
Metformin may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Tetracycline
Tetracycline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester)
Metformin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester)
Canagliflozin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Canagliflozin.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Canagliflozin.
Ticlopidine
Ticlopidine may decrease the excretion rate of Metformin which could result in a higher serum level.
Ticlopidine
Ticlopidine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tinidazole
Metformin may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Tinidazole
Tinidazole may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tinzaparin
The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Canagliflozin.
Tiopronin
Metformin may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiopronin
Tiopronin may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tiotropium
Metformin may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Tiotropium
Tiotropium may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tipranavir
The therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.
Tirofiban
Metformin may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Tirofiban
Tirofiban may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.
Tocopherol
Metformin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tocopherol
Canagliflozin may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tocopherylquinone
Canagliflozin may increase the hypotensive activities of Tocopherylquinone.
Tolcapone
Tolcapone may decrease the excretion rate of Metformin which could result in a higher serum level.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Canagliflozin.
Tolmetin
Tolmetin may decrease the excretion rate of Metformin which could result in a higher serum level.
Tolmetin
The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Canagliflozin.
Tolterodine
Metformin may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Tolterodine
Tolterodine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Tolvaptan
Tolvaptan may increase the excretion rate of Metformin which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate
Topiramate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Torasemide
The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.
Tramadol
Tramadol may decrease the excretion rate of Metformin which could result in a higher serum level.
Tramadol
Tramadol may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Trametinib
Metformin may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trametinib
Canagliflozin may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trandolapril
The risk or severity of lactic acidosis can be increased when Trandolapril is combined with Metformin.
Tranylcypromine
Tranylcypromine may increase the hypoglycemic activities of Metformin.
Treprostinil
Canagliflozin may increase the hypotensive activities of Treprostinil.
Triamcinolone
The therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone.
Triamterene
Triamterene may decrease the excretion rate of Metformin which could result in a higher serum level.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Canagliflozin.
Triazolam
Metformin may decrease the excretion rate of Triazolam which could result in a higher serum level.
Triazolam
Triazolam may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Triethylenetetramine
Metformin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Triethylenetetramine
Triethylenetetramine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Trifluridine
Metformin may decrease the excretion rate of Trifluridine which could result in a higher serum level.
Trifluridine
Trifluridine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Trimethoprim
The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Canagliflozin.
Trimetrexate
Metformin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Trimetrexate
Trimetrexate may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Triptorelin
The therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin.
Trospium
The serum concentration of Trospium can be decreased when it is combined with Metformin.
Vaborbactam
Metformin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Vaborbactam
Canagliflozin may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Vadadustat
The serum concentration of Canagliflozin can be increased when it is combined with Vadadustat.
Valaciclovir
Valaciclovir may decrease the excretion rate of Metformin which could result in a higher serum level.
Valaciclovir
Valaciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Valbenazine
Metformin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valbenazine
Canagliflozin may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib
The therapeutic efficacy of Metformin can be increased when used in combination with Valdecoxib.
Valdecoxib
The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Canagliflozin.
Valganciclovir
Metformin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Valganciclovir
Valganciclovir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Varenicline
Varenicline may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Vemurafenib
The therapeutic efficacy of Metformin can be increased when used in combination with Vemurafenib.
Vericiguat
The risk or severity of adverse effects can be increased when Canagliflozin is combined with Vericiguat.
Vilanterol
Metformin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Vilanterol
Canagliflozin may decrease the excretion rate of Vilanterol which could result in a higher serum level.
Viloxazine
Metformin may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Viloxazine
The metabolism of Canagliflozin can be decreased when combined with Viloxazine.
Vorinostat
The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat.
Vortioxetine
Metformin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Vortioxetine
Canagliflozin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Zaleplon
Metformin may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Zaleplon
Zaleplon may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Zanamivir
Metformin may decrease the excretion rate of Zanamivir which could result in a higher serum level.
Zanamivir
Zanamivir may decrease the excretion rate of Canagliflozin which could result in a higher serum level.
Ziprasidone
The therapeutic efficacy of Metformin can be decreased when used in combination with Ziprasidone.